Most notably, this has led to a commercially available test (ConfirmMDx for Prostate Cancer; MDx Health) with a reported negative predictive value of 90% in confirming negative biopsies based on qMSP analysis of APC, GSTP1, and RASSF139. Here, GSTP1 is linked to prostate carcinoma.